Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 14, 2024 16:30 ET
|
Marker Therapeutics
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and
Provides Business Update
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 14, 2024 16:30 ET
|
Marker Therapeutics
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
August 12, 2024 07:00 ET
|
Marker Therapeutics
HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
萬聯行在香港獲得Targretin®️（Bexarotene）用於皮膚T細胞淋巴瘤的上市批准
July 16, 2024 02:54 ET
|
MAIN LIFE CORPORATION LIMITED
香港和澳門的獲批為Targretin®️首次在中國區域內上市Bexarotene為國際臨床慣例用於治療復發性皮膚T細胞淋巴瘤(CTCL)的標準藥物 香港, July 16, 2024 (GLOBE NEWSWIRE) --...
万联行获得Targretin®（Bexarotene 贝沙罗汀）在香港用于皮肤T细胞淋巴瘤的市场批准
July 16, 2024 02:54 ET
|
MAIN LIFE CORPORATION LIMITED
香港和澳门的批准标志着Targretin®首次在中国上市贝沙罗汀代表国际临床实践中对复发性皮肤T细胞淋巴瘤(CTCL)的标准治疗 香港, July 16, 2024 (GLOBE NEWSWIRE) -- 万联行有限公司（“Main Life”）今天宣布Targretin®（贝沙罗汀）胶囊在香港获得上市许可，用于治疗至少一次系统治疗无效的皮肤T细胞淋巴瘤 （Cutaneous T-cell...
Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma
July 16, 2024 02:54 ET
|
MAIN LIFE CORPORATION LIMITED
Targretin® (Bexarotene) received Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma.
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 07:15 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies...
CARGO Therapeutics to Participate in Upcoming Investor Conferences
May 28, 2024 08:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 15, 2024 16:15 ET
|
Marker Therapeutics
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who...